Contact
QR code for the current URL

Story Box-ID: 79226

Wilex AG Grillparzerstr. 10 81675 München, Germany http://www.wilex.com
Contact Ms Juliane Giese +49 89 41313829
Company logo of Wilex AG
Wilex AG

WILEX successfully completes Phase II study with RENCAREX®* in combination with Interferon

RENCAREX® in combination with low dose Interferon alpha-2a leads to a 2 year survival rate of 57 % for patients with progressive metastatic renal cell cancer

(PresseBox) (Munich, )
Inactive

The publishing company has not yet activated this story.

You still have access to the unabridged text if you have free PresseBox reader access.

Log in or register free of charge
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.